Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Coherent Reports Record Sales and Profits

Photonics.com
Nov 2000
SANTA CLARA, Calif., Nov. 3 -- Citing its continued success in the lithography market, Coherent Inc. recorded its best-ever sales and profits during the final three months of fiscal year 2000. This year's fourth quarter sales reached $155.0 million, an increase of $23.3 million, or 18 percent, compared with forth quarter sales for the same 1999 period. Because of Lambda Physik AG's initial public offering, witch Coherent has a 60.4 percent stake in, Coherent's net income for the quarter rose to &$36;43.7 million, or $1.53 per diluted share, including a $32.3 million, or $1.13 per diluted share, after tax gain. Pro forma net income of $11.4 million (excluding the Lambda gain) represented a 56 percent increase ($4.1 million) compared to net income in the fourth quarter of the prior year. The current quarter sales and pro forma net income were 4 percent and 15 percent, respectively; an increase compared with this year's third quarter results.
Incoming orders for the quarter were $165.6 million, an increase of 17 percent over the same quarter last year. For the fiscal year, bookings and sales were $640.5 million and $568.3 million, respectively, representing a 33 percent and 21 percent increase compared with last year. Net income for the year was $68.6 million, or $2.51 per diluted share, including the Lambda gain. Pro forma net income for the year was $36.3 million, or $1.33 per diluted share, which represents a 61 percent increase over the prior year's pro forma net income of $22.6 million, or $0.92 per diluted share. The prior year's pro forma net income excludes the $10.7 million after tax charge, or $0.44 per diluted share, for in-process research and development associated with the Star Medical acquisition.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.